Hyperlipidemia, Familial CombinedHyperlipidemiasHeartHeart RateHeart FailureTriglyceridesHypolipidemic AgentsLipidsHeart DiseasesCholesterolHeart TransplantationHeart Defects, CongenitalCholesterol, LDLHypertriglyceridemiaFetal HeartHyperlipoproteinemia Type IVLipoproteinsRisk FactorsLipid MetabolismApolipoproteins EHeart ValvesCholesterol, HDLHypercholesterolemiaApolipoproteins BApolipoproteins CHeart AtriaApolipoprotein E2Lipoprotein LipaseApolipoprotein C-IIIFenofibrateLipoproteins, VLDLCoronary DiseaseXanthomatosisAnticholesteremic AgentsMyocardiumLiverHeart BlockArteriosclerosisTime FactorsApolipoproteinsLipoproteins, LDLObesityHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, VLDLDisease Models, AnimalDietary FatsMice, Inbred C57BLHyperlipoproteinemia Type IIGynostemmaReceptors, LDLHeart Arrest, InducedAtherosclerosisDiabetes MellitusHeart Function TestsCardiovascular DiseasesMyocardial IschemiaBlood GlucoseHyperlipoproteinemia Type IIIMyocardial ContractionBody WeightHeptanoic AcidsPoloxamerTreatment OutcomeMice, KnockoutMyocardial InfarctionDiet, AtherogenicApolipoprotein A-IRats, Sprague-DawleyCholesterol, DietaryInsulin ResistanceDiabetes Mellitus, Type 2HypertensionMyocytes, CardiacDyslipidemiasPostprandial PeriodInsulinProspective StudiesBezafibrateEpichlorohydrinFatty LiverRats, WistarFollow-Up StudiesApolipoproteins AHemodynamicsPyrrolesHyperlipoproteinemiasRetrospective StudiesSimvastatinBiological MarkersFatty Acids, NonesterifiedAge FactorsPhenotypeNephrotic SyndromeCardiac Output, LowVentricular Function, LeftHyperlipoproteinemia Type VGemfibrozilRisk AssessmentPravastatinDiabetes Complications